Table 3. Univariate and multivariate cox proportional hazard models for overall survival (OS) and disease-free survival (DFS) in all stage II colon cancer patients.
| OS | DFS | |||||||
|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | |||||
| HR (95%CI) | p* | HR (95%CI) | p* | HR (95%CI) | p* | HR (95%CI) | p* | |
| DDA1/p65 | ||||||||
| Both negative | – | – | – | – | ||||
| One positive | 1.73 (0.98, 8.43) | 0.044* | 2.17 (1.57, 4.94) | 0.054 | 1.87 (1.23, 4.92) | 0.037* | 4.33 (1.59, 11.17) | 0.021* |
| Both positive | 8.77 (3.01, 15.26) | 0.002* | 7.06 (5.12, 14.38) | 0.026* | 5.69 (3.46, 10.77) | < 0.001* | 6.70 (2.88, 16.05) | 0.011* |
| DDA1 | ||||||||
| Negative | – | – | – | – | ||||
| Weak | 3.02 (1.47, 8.53) | < 0.001* | 2.42 (1.35, 6.81) | 0.003* | 3.89 (1.87, 9.79) | 0.043* | 2.77 (1.09, 6.37) | 0.017* |
| Strong | 6.58 (3.42, 14.98) | 0.035* | 5.14 (1.46, 12.17) | 0.029* | 4.87 (1.74, 14.10) | < 0.001* | 2.98 (1.46, 6.18) | 0.007* |
| P65 | ||||||||
| Negative | – | – | – | – | ||||
| Positive | 1.66 (0.73, 4.99) | 0.063 | 2.05 (1.33, 7.78) | 0.002* | 1.36 (0.78–7.21) | < 0.001* | ||
| Age | ||||||||
| < 65 | – | – | – | – | ||||
| ≥ 65 | 0.87 (0.57, 1.35) | 0.541 | 0.87 (0.57, 1.35) | 0.542 | ||||
| Gender | ||||||||
| Female | – | – | – | – | ||||
| Male | 1.28 (0.83, 1.98) | 0.263 | 1.29 (0.84, 1.99) | 0.246 | ||||
| Location | ||||||||
| Right | – | – | – | – | ||||
| Transverse | 0.93 (0.59, 1.47) | 0.060 | 0.92 (0.58, 1.45) | 0.709 | ||||
| Left | 0.26 (0.06, 1.06) | 0.057 | 0.27 (0.06, 1.09) | 0.065 | ||||
| p T stage | ||||||||
| pT3 | – | – | – | – | ||||
| pT4a | 3.11 (1.78, 5.45) | 0.021* | 1.56 (0.31, 11.00) | 0.046* | 2.32 (1.18, 5.51) | 0.029* | 1.40 (0.72, 3.70) | 0.032* |
| pT4b | 6.21 (3.75, 15.29) | 0.007* | 3.80 (1.47, 10.36) | 0.026* | 4.65 (1.39, 12.07) | 0.009* | 2.87 (1.51, 6.48) | 0.004* |
| AJCC stage | ||||||||
| IIA | – | – | – | – | ||||
| IIB | 3.11 (1.78, 5.45) | 0.021* | 1.56 (0.31, 11.00) | 0.046* | 2.32 (1.18, 5.52) | 0.029* | 1.40 (0.72, 3.70) | 0.032* |
| IIC | 6.21 (3.75, 15.30) | 0.007* | 3.80 (1.47, 10.36) | 0.026* | 4.65 (1.39, 12.07) | 0.009* | 2.87 (1.51, 6.48) | 0.004* |
| Vessel invasion | ||||||||
| No | – | – | – | – | ||||
| Yes | 1.14 (0.62, 2.10) | < 0.001* | 1.07 (0.67–3.31) | < 0.001* | 2.10 (1.05, 5.18) | < 0.001* | 2.26 (1.35–5.77) | < 0.001* |
| Differentiation | ||||||||
| Well | – | – | – | – | ||||
| Moderate | 3.73 (1.35, 10.31) | 0.013* | 1.05 (0.92, 1.73) | 0.031* | 2.04 (1.03, 6.02) | < 0.001* | 1.14 (0.97–5.52) | 0.046* |
| Poor | 8.45 (2.80, 14.52) | < 0.001* | 2.16 (1.09, 5.27) | < 0.001* | 4.34 (1.08, 10.22) | 0.015* | 2.03 (1.14–8.93) | 0.034* |
| Chemotherapy | ||||||||
| 5-FU/LV | – | – | ||||||
| FOLFOX4 | 0.68 (0.36–1.05) | 0.048 | 0.74 (0.54–1.48) | 0.262 | 0.72 (0.52–1.20) | 0.034* | 0.65 (0.49–1.18) | 0.067 |
HR: hazard ratio; CI: confidence interval.
*
p < 0.05 indicated that the 95% CI of HR was not including 1.